Microbiologics and Microbix Partner on Viral Controls for Diagnostics
By LabMedica International staff writers Posted on 12 Apr 2015 |
Image: Under a new partnership, inactivated viruses from Microbix Biosystems, Inc. will be incorporated into a line of full process controls under Microbiologics’ Helix Elite Molecular Standards brand as well as instrument-specific quality control sets (Photo courtesy of Microbiologics).
Microbiologics, Inc. (St. Cloud, MN, USA) has entered into an agreement to source inactivated viruses from Microbix Biosystems, Inc. (Mississauga, ON, Canada) to be incorporated into a line of full process controls under Microbiologics’ Helix Elite Molecular Standards brand as well as instrument-specific quality control sets.
Diagnostic assays are dependent on controls to demonstrate test performance characteristics and staff proficiency, but laboratories struggle to identify adequate biomaterials and frequently use clinical samples that may not be well characterized or consistently available. Increased regulation requires that labs more carefully consider the source, quality, and format of their molecular and culture-based control materials. This partnership will combine both companies’ expertise in biomaterial development, preservation, and distribution to create highly stable viral controls for molecular testing.
“We are pleased to use Microbix materials in Microbiologics products as they have a strong, global reputation for high-quality viral preparations for the vaccine and immunodiagnostics markets” Brian Beck, PhD, vice president, Molecular Products and Services, Microbiologics, “Incorporation of Microbix viral materials into our lyophilized, molecular-compatible formats complements our existing synthetic standards and extends our catalog to include extraction controls for gastrointestinal, respiratory, blood borne, and sexually transmitted viral pathogens.”
Phil Casselli, senior vice president, Business Development, Microbix, said, “We are pursuing a multipronged approach to exploit the high-growth molecular diagnostics marketplace. Microbiologics has relationships with instrument manufacturers, as well as large-scale distribution capabilities, making them an ideal partner to help expand the reach of our developing molecular program. Our unique isolates offering complements Microbiologics’ strengths. We will both be focused on what we do best in this relationship.”
“As part of our commitment to a safer, healthier world, Microbiologics continues to partner with industry leaders such as Microbix to develop advanced, practical controls that support the evolving field of molecular microbiology,” said Brad Goskowicz, Microbiologics’ CEO, “We look forward to working with molecular diagnostic manufacturers to ensure that clinical laboratories have the appropriate and highest quality control material for their instruments and assays.”
Related Links:
Microbiologics
Microbix Biosystems
Helix Elite, CE-marked IVD molecular standards
Diagnostic assays are dependent on controls to demonstrate test performance characteristics and staff proficiency, but laboratories struggle to identify adequate biomaterials and frequently use clinical samples that may not be well characterized or consistently available. Increased regulation requires that labs more carefully consider the source, quality, and format of their molecular and culture-based control materials. This partnership will combine both companies’ expertise in biomaterial development, preservation, and distribution to create highly stable viral controls for molecular testing.
“We are pleased to use Microbix materials in Microbiologics products as they have a strong, global reputation for high-quality viral preparations for the vaccine and immunodiagnostics markets” Brian Beck, PhD, vice president, Molecular Products and Services, Microbiologics, “Incorporation of Microbix viral materials into our lyophilized, molecular-compatible formats complements our existing synthetic standards and extends our catalog to include extraction controls for gastrointestinal, respiratory, blood borne, and sexually transmitted viral pathogens.”
Phil Casselli, senior vice president, Business Development, Microbix, said, “We are pursuing a multipronged approach to exploit the high-growth molecular diagnostics marketplace. Microbiologics has relationships with instrument manufacturers, as well as large-scale distribution capabilities, making them an ideal partner to help expand the reach of our developing molecular program. Our unique isolates offering complements Microbiologics’ strengths. We will both be focused on what we do best in this relationship.”
“As part of our commitment to a safer, healthier world, Microbiologics continues to partner with industry leaders such as Microbix to develop advanced, practical controls that support the evolving field of molecular microbiology,” said Brad Goskowicz, Microbiologics’ CEO, “We look forward to working with molecular diagnostic manufacturers to ensure that clinical laboratories have the appropriate and highest quality control material for their instruments and assays.”
Related Links:
Microbiologics
Microbix Biosystems
Helix Elite, CE-marked IVD molecular standards
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia